Breaking News Instant updates and real-time market news.

PTLA

Portola Pharmaceuticals

$37.77

0.14 (0.37%)

, CELG

Celgene

$91.23

0.92 (1.02%)

08:04
08/09/18
08/09
08:04
08/09/18
08:04

Portola Pharmaceuticals names Ernie Meyer as CHRO

Portola Pharmaceuticals (PTLA) announced the appointment of Ernie Meyer as executive vice president and chief human resources officer, effective August 20. As a member of the Executive Committee, Mr. Meyer will report to John T. Curnutte, M.D., Ph.D., interim co-president of Portola and head of research and development, with responsibility for leading the development and execution of the Company's global human resources strategy. Meyer joins Portola from Celgene (CELG), where he spent more than 13 years in positions of increasing scope and responsibility. Most recently, Mr. Meyer served as executive vice president of human resources & corporate services.

PTLA

Portola Pharmaceuticals

$37.77

0.14 (0.37%)

CELG

Celgene

$91.23

0.92 (1.02%)

  • 09

    Aug

  • 25

    Aug

  • 29

    Oct

PTLA Portola Pharmaceuticals
$37.77

0.14 (0.37%)

05/07/18
SBSH
05/07/18
NO CHANGE
Target $64
SBSH
Buy
Portola Pharmaceuticals price target raised to $64 from $58 at Citi
Citi analyst Yigal Nochomovitz raised his price target for Portola Pharmaceuticals to $64 following the FDA approval of Andexxa. The analyst keeps a Buy rating on the shares.
05/07/18
OPCO
05/07/18
NO CHANGE
Target $80
OPCO
Outperform
Portola Pharmaceuticals price target raised to $80 from $67 at Oppenheimer
Oppenheimer analyst Jay Olson raised his price target for Portola Pharmaceuticals to $80 from $67 after AndexXa received FDA approval as the first and only antidote indicated for patients treated with rivaroxaban and apixaban when reversal is needed in the case of life-threatening or uncontrolled bleeding. The analyst believes potential drivers of upside include AndexXa likely expanding factor Xa use and label extensions, U.S. approval of Gen2 manufacturing to expand capacity, European CHMP opinion in Q4 and cerdulatinib data at ASCO. Olson reiterates an Outperform rating on the shares.
05/07/18
MSCO
05/07/18
NO CHANGE
Target $46
MSCO
Equal Weight
Portola price target raised to $46 from $31 at Morgan Stanley
Morgan Stanley analyst Matthew Harrison raised his price target on Portola Pharmaceuticals to $46 following the FDA approval of AndexXa, calling it a significant positive. However, he maintains an Equal Weight rating on the shares, as he expects the stock to trade with the market given the limited launch will not allow investors to gauge true demand until 2019.
06/14/18
SBSH
06/14/18
NO CHANGE
SBSH
Buy
Portola not planning sale despite CEO transition, says Citi
Citi analyst Yigal Nochomovitz asked Portola Pharmaceuticals if the CEO transition means the company is potentially up for sale. Management emphasized that the CEO transition should not be interpreted as meaning they are planning to sell the company, Nochomovitz tells investors in a research note. He points out that management reiterated they are working towards advancing the company commercially. With two approved drugs in thrombosis, Portola views itself as well positioned to attract new talent to continue to build its sales force, Nochomovitz writes after speaking to the company. He keeps a Buy rating on the shares.
CELG Celgene
$91.23

0.92 (1.02%)

07/24/18
JPMS
07/24/18
NO CHANGE
JPMS
Overweight
Celgene positive headline streak continues, says JPMorgan
Last night's positive topline data for Revlimid plus Rituxan in relapsed/refractory indolent lymphoma is a "clear win" at a time when Celgene "really needed a string of favorable events," JPMorgan analyst Cory Kasimov tells investors in a research note titled "Positive Headline Streak Continues with AUGMENT." The analyst sees this indication as a "meaningful" near-term sales opportunity for the franchise prior to loss of exclusivity, potentially $600M in the U.S. alone. He expects the positive data to "modestly bolster sentiment" into Celgene's Q2 results. Kasimov keeps an Overweight rating on the shares.
07/26/18
PIPR
07/26/18
NO CHANGE
Target $95
PIPR
Neutral
Longer term concerns remain despite 'impressive' Q2 for Celgene, says Piper Jaffray
Piper Jaffray analyst Christopher Raymond reiterates a Neutral rating and $95 price target for Celgene despite a "solid" Q2 results. With an "impressive" $110M Revlimid beat this quarter and $200M guidance increase, Celgene continues its pattern of strong Q2 performance, he notes. But despite this commercial execution, Raymond's concerns with respect to the company's ability to diversify away from Revlimid remain and he continues to prefer the sidelines on this name.
07/30/18
RHCO
07/30/18
NO CHANGE
Target $101
RHCO
Hold
Celgene price target raised to $101 from $96 at SunTrust
SunTrust analyst Yatin Suneja raised his price target on Celgene to $101 after its Q2 results, saying the company saw "good performances from all core products except Otezla and Abraxan", while its updated FY18 outlook also reflects its larger than anticipated share buyback. Suneja further notes that Celgene's pipeline assets ozanimod, fedratinib, luspatercept and the CAR-T programs are all progressing towards filings, which may help the company diversify its pipeline away from Revlimid. The analyst also keeps his Hold rating, noting that any near-term contribution from its extensive pipeline are likely to be limited.
08/08/18
RBCM
08/08/18
NO CHANGE
Target $110
RBCM
Outperform
RBC Capital revisits idea of Celgene going private after Tesla proposal
Following yesterday's news that Tesla (TSLA) CEO Elon Musk would like to see his company go private, RBC analyst Brian Abrahams revisited his prior analysis of whether Celgene (CELG) should go private in order to better capture the medium-term value of future Revlimid cash flows not being appreciated by public markets and avoid volatility as it transitions to a post-Revlimid business model. Though acknowledging that the two companies are in completely different industries, he thinks the example of Musk shows that performing such a transaction on a large company "may not be completely unrealistic," Abrahams said. Such an LBO, or perhaps more likely an acquisition by a larger pharmaceutical company, could possibly help capture more value from Celgene's commercial and pipeline products, concludes Abrahams, who has an Outperform rating and $110 price target on Celgene shares.

TODAY'S FREE FLY STORIES

TBPH

Theravance Biopharma

$27.53

-0.575 (-2.05%)

15:53
12/13/18
12/13
15:53
12/13/18
15:53
Recommendations
Theravance Biopharma analyst commentary  »

Piper Jaffray impressed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CC

Chemours

$27.13

0.47 (1.76%)

15:50
12/13/18
12/13
15:50
12/13/18
15:50
Options
Put spreads in Chemours Company as a position is adjusted »

Put spreads in Chemours…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMZN

Amazon.com

$1,652.23

-11.17 (-0.67%)

, JNPR

Juniper

$28.18

-0.27 (-0.95%)

15:46
12/13/18
12/13
15:46
12/13/18
15:46
Periodicals
Amazon replacing some Juniper equipment with homegrown, Information says »

Hopes that Juniper (JNPR)…

AMZN

Amazon.com

$1,652.23

-11.17 (-0.67%)

JNPR

Juniper

$28.18

-0.27 (-0.95%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Dec

  • 20

    Dec

  • 29

    Jan

RH

RH

$129.68

-6.53 (-4.79%)

15:45
12/13/18
12/13
15:45
12/13/18
15:45
Options
Restoration Hardware call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UBER

Uber

$0.00

(0.00%)

, SBUX

Starbucks

$66.72

0.62 (0.94%)

15:44
12/13/18
12/13
15:44
12/13/18
15:44
Hot Stocks
Starbucks expanding partnership with Uber Eats »

During Starbucks'…

UBER

Uber

$0.00

(0.00%)

SBUX

Starbucks

$66.72

0.62 (0.94%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

  • 14

    Dec

KO

Coca-Cola

$49.47

0.27 (0.55%)

, KDP

Keurig Dr Pepper

$26.14

0.03 (0.11%)

15:37
12/13/18
12/13
15:37
12/13/18
15:37
On The Fly
UBS cuts Coca-Cola rating, says sell Monster Beverage »

As part of his initiation…

KO

Coca-Cola

$49.47

0.27 (0.55%)

KDP

Keurig Dr Pepper

$26.14

0.03 (0.11%)

TAP

Molson Coors

$63.21

0.2 (0.32%)

MNST

Monster Beverage

$53.51

-3.93 (-6.84%)

SAM

Boston Beer

$269.74

-4.34 (-1.58%)

FIZZ

National Beverage

$79.97

-4.15 (-4.93%)

PEP

PepsiCo

$118.31

1.33 (1.14%)

STZ

Constellation Brands

$183.03

-3.67 (-1.97%)

CCE

Coca-Cola European Partners

$0.00

(0.00%)

BFA

Brown-Forman, also tag with BF.A, BF.B

$0.00

(0.00%)

BFB

Brown-Forman, also tag with BF.A, BF.B

$0.00

(0.00%)

BF.A

Brown-Forman, also tag with BFA, BFB

$47.95

1.41 (3.03%)

BF.B

Brown-Forman, also tag with BFA, BFB

$47.43

0.95 (2.04%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

  • 14

    Dec

  • 18

    Dec

  • 18

    Dec

  • 15

    Feb

  • 03

    Mar

SPY

SPDR S&P 500 ETF Trust

$264.81

-0.72 (-0.27%)

, SPX

S&P 500

$0.00

(0.00%)

15:22
12/13/18
12/13
15:22
12/13/18
15:22
Periodicals
Short interest in S&P 500 ETF 'jumps' to 5.3%, Bloomberg says »

Bloomberg, citing data…

SPY

SPDR S&P 500 ETF Trust

$264.81

-0.72 (-0.27%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DTEA

DavidsTea

$1.95

0.06 (3.17%)

15:19
12/13/18
12/13
15:19
12/13/18
15:19
Options
Davids Tea options imply 19.7% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

15:17
12/13/18
12/13
15:17
12/13/18
15:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

15:16
12/13/18
12/13
15:16
12/13/18
15:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SBUX

Starbucks

$66.80

0.7 (1.06%)

15:11
12/13/18
12/13
15:11
12/13/18
15:11
Hot Stocks
Starbucks says starting new rewards program in China »

Starbucks executives…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

  • 14

    Dec

FFIN

First Financial

$60.53

-0.8 (-1.30%)

15:08
12/13/18
12/13
15:08
12/13/18
15:08
Hot Stocks
First Financial elects John Ruzicka Chief Information Officer »

First Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jan

RDNT

RadNet

$12.61

0.05 (0.40%)

15:08
12/13/18
12/13
15:08
12/13/18
15:08
Hot Stocks
RadNet and MemorialCare expand joint venture »

MemorialCare and RadNet…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

15:05
12/13/18
12/13
15:05
12/13/18
15:05
General news
Treasury Closing Summary: »

Treasury Closing Summary:…

SFLY

Shutterfly

$43.18

-1.65 (-3.68%)

15:04
12/13/18
12/13
15:04
12/13/18
15:04
Recommendations
Shutterfly analyst commentary  »

Shutterfly weakness…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HIIQ

Health Insurance Innovations

$35.90

5.835 (19.41%)

15:04
12/13/18
12/13
15:04
12/13/18
15:04
Recommendations
Health Insurance Innovations analyst commentary  »

Settlement should remove…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

COST

Costco

$225.93

-1.89 (-0.83%)

15:04
12/13/18
12/13
15:04
12/13/18
15:04
Options
Costco options imply 5.4% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

HIIQ

Health Insurance Innovations

$35.90

5.835 (19.41%)

15:02
12/13/18
12/13
15:02
12/13/18
15:02
Recommendations
Health Insurance Innovations analyst commentary  »

Health Insurance…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

MRVL

Marvell

$15.53

0.18 (1.17%)

15:00
12/13/18
12/13
15:00
12/13/18
15:00
Options
Size time spread in Marvell Tech following an analyst upgrade »

Size time spread in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Jan

  • 08

    Jan

G

Genpact

$28.14

-0.27 (-0.95%)

, EXLS

ExlService

$55.76

0.13 (0.23%)

14:57
12/13/18
12/13
14:57
12/13/18
14:57
Conference/Events
William Blair IT/BPO services analysts to hold analyst/industry conference call »

India IT/BPO Services…

G

Genpact

$28.14

-0.27 (-0.95%)

EXLS

ExlService

$55.76

0.13 (0.23%)

WNS

WNS Holdings

$46.99

-0.82 (-1.72%)

GLOB

Globant

$55.66

-1.37 (-2.40%)

PRFT

Perficient

$23.49

-0.28 (-1.18%)

VRTU

Virtusa

$41.05

1.2 (3.01%)

INFY

Infosys

$9.85

0.19 (1.97%)

WIT

Wipro

$5.30

0.19 (3.72%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SBUX

Starbucks

$66.61

0.51 (0.77%)

14:56
12/13/18
12/13
14:56
12/13/18
14:56
Hot Stocks
Breaking Hot Stocks news story on Starbucks »

Starbucks says 80% of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

  • 14

    Dec

AAPL

Apple

$170.45

1.36 (0.80%)

, INTC

Intel

$48.11

0.28 (0.59%)

14:55
12/13/18
12/13
14:55
12/13/18
14:55
Recommendations
Apple, Intel analyst commentary  »

Lynx questions…

AAPL

Apple

$170.45

1.36 (0.80%)

INTC

Intel

$48.11

0.28 (0.59%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Jan

SBUX

Starbucks

$66.48

0.38 (0.57%)

14:50
12/13/18
12/13
14:50
12/13/18
14:50
Options
Heavy trading in Starbucks Weekly options during the company's Investor Day »

Heavy trading in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

  • 14

    Dec

ADBE

Adobe

$247.50

2.06 (0.84%)

14:49
12/13/18
12/13
14:49
12/13/18
14:49
Options
Adobe options imply 7.3% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

CMG

Chipotle

$472.11

0.91 (0.19%)

, DANOY

Danone

$0.00

(0.00%)

14:44
12/13/18
12/13
14:44
12/13/18
14:44
Hot Stocks
Chipotle announces hiring of Chief Legal Officer and Chief Development Officer »

Chipotle Mexican Grill…

CMG

Chipotle

$472.11

0.91 (0.19%)

DANOY

Danone

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

  • 14

    Dec

  • 06

    Feb

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.